Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Exact Sciences despite higher revenues, with a focus on how actual results will compare to estimates [1][2]. Financial Expectations - Exact Sciences is expected to report a quarterly loss of $0.32 per share, reflecting an 18.5$703.56 million, indicating an 8.8% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 7.41% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Exact Sciences is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +1.59% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [8]. - Exact Sciences currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Exact Sciences was expected to post a loss of $0.20 per share but actually reported a loss of$0.21, resulting in a -5% surprise [12]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [13]. Industry Context - In the broader Zacks Medical - Biomedical and Genetics industry, Axsome Therapeutics is expected to report a loss of $0.99 per share, a 35.6$117.84 million, up 64.7% from the previous year [17]. - Axsome's consensus EPS estimate has been revised down by 7% over the last 30 days, leading to a negative Earnings ESP of -4.51% [18].